Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 14 Issue 4, December 2020

Volume 14 Issue 4

In this issue...

• Pfizer’s strategy for partnering success

• Dealmaking in 2020 regains pace

• The promise of microbiome therapeutics draws closer

• Getting to the heart of genetic therapies

Transparent human chest showing heart and lungs. Cultura Creative Ltd / Alamy Stock Photo.

Pfizer’s strategy for partnering success

The promise of microbiome therapeutics draws closer

    Feature

  • Profiles

  • Advertisement Feature |

    Biosortia is building the world’s largest library of microbiome-derived compounds for therapeutic and other applications, by leveraging the company’s microbial harvesting platform to sample and mine aquatic microbiomes at unprecedented scales with sustainable and environmentally friendly approaches. Biosortia is seeking partners interested in accessing compounds and chemistries to develop biologically relevant small molecule leads.

    • Biosortia Pharmaceuticals
  • Advertisement Feature |

    Axial Therapeutics focuses on the gut–brain axis to develop therapeutics to mitigate central nervous system disorders and conditions. The company has built a pipeline of novel small molecules with lead programs in autism spectrum disorder and Parkinson’s disease.

    • Axial Biotherapeutics
  • Advertisement Feature |

    Symberix is integrating gut microbiome-targeted ‘symbiotic drugs’ and precision medicine strategies into small-molecule drug discovery, and is seeking corporate partners who are ready to transform pharmaceutical R&D and life cycle management.

    • Symberix, Inc.
  • Advertisement Feature |

    Maximizing the potential of the resident gut microbiome, Kaleido Biosciences is developing novel glycans with the ability to change the metabolic output of the microbiome and have a clinically significant impact across a broad range of diseases.

    • Kaleido Biosciences
  • Advertisement Feature |

    Viome has developed the world’s largest metatranscriptomic platform for analyzing human and microbial functions at the molecular level to discover novel mechanisms underlying chronic diseases, cancer, and aging. The company is seeking partners to develop diagnostics, companion diagnostics, and therapeutics based on targets identified using the Viome platform.

    • Viome, Inc.
  • Advertisement Feature |

    RevoluGen has designed Fire Monkey, a fast, easy-to-use spin column that extracts optimal DNA for long-read sequencing and is already being used in a number of applications.

    • Revolugen Ltd
  • Advertisement Feature |

    Novome’s novel platform develops genetically engineered microbial medicines (GEMMs) for chronic disease, offering the potential to act as a delivery system for novel therapeutic functionality, including proteins and peptides, into the gut microenvironment.

    • Novome Biotechnologies
  • Advertisement Feature |

    Genome & Company is developing a microbiome-based add-on therapy for programmed cell death 1/programmed cell death 1 ligand 1 inhibitors. It is also developing novel targeted immune checkpoint inhibitors and believes these two approaches could be combined for personalized therapy.

    • Genome & Company

Dealmaking in 2020 regains pace

    Feature

  • Profiles

  • Advertisement Feature |

    Knopp Biosciences’ investigational, first-in-class drug, dexpramipexole, holds promise for patients with asthma and eosinophil-associated diseases.

    • Knopp Biosciences
  • Advertisement Feature |

    Kancera, the Swedish company developing drugs to block hyperinflammation and protect function of vital organs, has commenced a phase 2 clinical trial of KAND567, a drug candidate which antagonizes the fractalkine receptor believed to trigger life-threatening inflammatory processes in COVID-19 and heart attack patients.

    • Kancera AB
  • Advertisement Feature |

    Hofseth BioCare is transforming marine raw materials into products to improve worldwide health conditions including treatments for gastrointestinal diseases, respiratory disorders and cardiovascular health.

    • Hofseth Biocare ASA
  • Advertisement Feature |

    NovaGo Therapeutics is developing a first-in-class fully human antibody therapy to treat diabetic retinopathy. With its novel disease-modifying mode of action, it could save the sight of the many patients who respond poorly to current treatments.

    • NovaGo Therapeutics AG
  • Advertisement Feature |

    Privately held Creatv MicroTech has developed LifeTracDx tests to detect cancer at the earliest stages, and for providing diagnoses to guide cancer treatments, thereby saving and improving lives.

    • Creatv MicroTech
  • Advertisement Feature |

    3T Biosciences has developed an immune response-guided approach for identifying pharmacologically active T cell receptors and their targets in solid tumors. With a pipeline of therapeutics targeting novel tumor antigens, 3T is seeking partners to advance these programs.

    • 3T Biosciences
  • Advertisement Feature |

    IGY Life Sciences has optimized the sustainable generation of highly specific and efficacious egg-derived IgY antibodies for human and animal health. The company’s pipeline includes marketed immune and sports health products, and lead compounds against COVID-19 and African swine fever.

    • IGY Life Sciences
  • Advertisement Feature |

    By reprogramming the tumor microenvironment Kineta is developing an anti-VISTA immuno-oncology therapy for the treatment of a variety of cancers, including gastric, ovarian, lung and pancreatic cancers.

    • Kineta, Inc.
  • Advertisement Feature |

    RubrYc Therapeutics has established an antibody discovery engine for the development of epitope-targeted biotherapeutics. Through machine learning, the platform helps reveal natural subdominant and alternative epitopes to target for optimized bio-superior design and as access points to traditionally ‘undruggable’ proteins.

    • RubrYc Therapeutics

Getting to the heart of genetic therapies

    Feature

  • News Feature |

    The maturation of oligonucleotide and gene therapies, and the birth of the gene editing revolution, are spurring innovation in the cardiovascular and metabolic disease space.

    • Mark Zipkin
  • Profiles

  • Advertisement Feature |

    Swiss-based DiNAQOR has developed a revolutionary gene therapy platform which combines gene-vector-promoter constructs with loco-regional delivery to the heart for the treatment of cardiovascular diseases. With its first AAV gene therapy program, DiNA-001, in development for the treatment of MYBPC3 hypertrophic cardiomyopathy (HCM), the company and its platform is attracting significant partnering interest.

    • DiNAQOR AG
  • Advertisement Feature |

    By combining machine learning with multiple proteins and proprietary algorithms, Prevencio has developed a portfolio of HART tests that accurately diagnose cardiovascular diseases. Prevencio also offers custom diagnostic services.

    • Prevencio
  • Advertisement Feature |

    Actimed Therapeutics is developing anabolic/catabolic transforming agents: a new class of agents to treat cachexia, an often fatal condition associated with many chronic diseases including cancer.

    • Actimed Therapeutics

Search

Quick links